ABL Bio showed an upward trend of more than 2% during the session, stabilizing in the 100,000-won range. As investment sentiment toward growth stocks improves along with a strong U.S. stock market, buying interest is flowing into domestic bio stocks.

During the morning session on the 1st, ABL Bio is trading at 102,100 won, up 2,600 won (2.61%) from the previous trading day. It continued its upward trend from early in the session, rising to around 103,000 won at one point, and has since maintained the 100,000-won level with a steady performance. Trading volume has exceeded 570,000 shares.

U.S. Stock Market AI Strength and Improved Bio Investment Sentiment

Overnight, major U.S. stock market indices rose together, led by gains in large-cap artificial intelligence (AI)-related tech stocks. As risk appetite expands, investment sentiment toward bio and growth stocks is also improving in the domestic market. Recently, the bio sector has been gradually recovering its investment sentiment, driven by the combination of strong U.S. tech stocks and expectations of interest rate cuts. Buy-the-dip flows are entering companies with high growth potential, leading to stock-specific differentiation.

Expectations for Bispecific Antibody Platform and Technology Transfer

ABL Bio is developing various new drug candidates based on its bispecific antibody platform technology, and expectations for co-development and technology transfers with global pharmaceutical companies are steadily growing. The market assesses that R&D achievements and pipeline progress could have a positive impact on the company's enterprise value.

The market views future clinical trial progress, the possibility of technology transfers, global bio investment sentiment, and changes in supply and demand from foreign and institutional investors as key variables that will determine ABL Bio's stock price trajectory.

[This article was written with the assistance of AI. This article does not constitute investment advice, and the final decision and responsibility for investments lie with the investor.]